Xact Kapitalforvaltning’s Atara Biotherapeutics ATRA Stock Holding History

Xact Kapitalforvaltning’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-324	Closed	-$322K	–	1443
2019 Q1	$322K	Buy	324 +88	+37%	+$81.8K	0.01%	1181
2018 Q4	$205K	Hold	236	–	–	0.01%	1430
2018 Q3	$244K	Buy	+236	New	+$231K	0.01%	1472

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Xact Kapitalforvaltning's ATRA Position: Q2 2019 in Review

Xact Kapitalforvaltning sold out of Atara Biotherapeutics (ATRA) in Q2 2019, closing a stake of 324 shares — an estimated $322K sold.

Xact Kapitalforvaltning first reported a position in ATRA in Q3 2018 and held it in 3 quarters. The position peaked at $322K in Q1 2019. 116 funds tracked by Wall St. Rank hold ATRA as of Q2 2019.

Xact Kapitalforvaltning reported no remaining Atara Biotherapeutics position as of Q2 2019 after selling out during the quarter.
Xact Kapitalforvaltning sold 324 Atara Biotherapeutics shares in Q2 2019, an estimated $322K.
Xact Kapitalforvaltning first reported a position in Atara Biotherapeutics in Q3 2018 and held it in 3 quarters.
Xact Kapitalforvaltning's Atara Biotherapeutics position peaked at $322K in Q1 2019.
116 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2019.

Based on Xact Kapitalforvaltning's 13F filing for Q2 2019, filed 12 Jul 2019.